Unlocking the Epigenetic Symphony: Histone Acetylation’s Impact on Neurobehavioral Change in Neurodegenerative Disorders

References

• Basavarajappa BS , Shivakumar M , Joshi V , Subbanna S . Endocannabinoid system in neurodegenerative disorders. J. Neurochem. 142(5), 624–648 (2017).
   PubMed Web of Science ®Google Scholar
• Ferrari R , Kapogiannis D , Huey ED , Momeni P . FTD and ALS: a tale of two diseases. Curr. Alzheimer Res. 8(3), 273–294 (2011).
   PubMed Web of Science ®Google Scholar
• Gibson SB , Figueroa KP , Bromberg MB , Pulst SM , Cannon-Albright L . Familial clustering of ALS in a population-based resource. Neurology 82(1), 17–22 (2014).
   PubMed Web of Science ®Google Scholar
• Keller MF , Ferrucci L , Singleton AB et al. Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol 71(9), 1123–1134 (2014).
   PubMed Web of Science ®Google Scholar
• Ridge PG , Mukherjee S , Crane PK , Kauwe JS . Alzheimer’s disease genetics C. Alzheimer’s disease: analyzing the missing heritability. PLOS ONE 8(11), e79771 (2013).
   PubMed Web of Science ®Google Scholar
• Singleton A , Hardy J . The evolution of genetics: Alzheimer’s and Parkinson’s diseases. Neuron 90(6), 1154–1163 (2016).
   PubMed Web of Science ®Google Scholar
• Aguzzi A , Kampmann M . Neurodegeneration enters the era of functional genomics. Science 381(6662), eadk5693 (2023).
   PubMedGoogle Scholar
• Price DL , Sisodia SS , Borchelt DR . Genetic neurodegenerative diseases: the human illness and transgenic models. Science 282(5391), 1079–1083 (1998).
   PubMed Web of Science ®Google Scholar
• Berson A , Nativio R , Berger SL , Bonini NM . Epigenetic regulation in neurodegenerative diseases. Trends Neurosci. 41(9), 587–598 (2018).
   PubMed Web of Science ®Google Scholar
• Lozupone M , Dibello V , Sardone R et al. The impact of apolipoprotein E (APOE) epigenetics on aging and sporadic Alzheimer’s disease. Biology (Basel) 12(12), (2023).
   PubMedGoogle Scholar
• Wang K , Liu H , Hu Q et al. Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct. Target Ther. 7(1), 374 (2022).
   PubMed Web of Science ®Google Scholar
• Zhou LT , Liu D , Kang HC et al. Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease. Sci. Adv. 9(16), eabq7105 (2023).
   PubMed Web of Science ®Google Scholar
• Waddington C . The epigenotype. Endeavour 1, 18–20 (1942).
   Google Scholar
• Wood MA , Hawk JD , Abel T . Combinatorial chromatin modifications and memory storage: a code for memory? Learn. Mem. 13(3), 241–244 (2006).
   PubMed Web of Science ®Google Scholar
• Arrowsmith CH , Bountra C , Fish PV , Lee K , Schapira M . Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11(5), 384–400 (2012).
   PubMed Web of Science ®Google Scholar
• Bernstein BE , Meissner A , Lander ES . The mammalian epigenome. Cell 128(4), 669–681 (2007).
   PubMed Web of Science ®Google Scholar
• Meaney MJ . Epigenetics and the biological definition of gene x environment interactions. Child Dev. 81(1), 41–79 (2010).
   PubMed Web of Science ®Google Scholar
• Portela A , Esteller M . Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Bonasio R , Tu S , Reinberg D . Molecular signals of epigenetic states. Science 330(6004), 612–616 (2010).
   PubMed Web of Science ®Google Scholar
• Wu C , Morris JR . Genes, genetics, and epigenetics: a correspondence. Science 293(5532), 1103–1105 (2001).
   PubMed Web of Science ®Google Scholar
• Migliore L , Coppede F . Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. 667(1–2), 82–97 (2009).
   PubMed Web of Science ®Google Scholar
• Migliore L , Coppede F . Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics. Nat. Rev. Neurol. 18(11), 643–660 (2022).
   PubMed Web of Science ®Google Scholar
• Bellver-Sanchis A , Pallas M , Grinan-Ferre C . The contribution of epigenetic inheritance processes on age-related cognitive decline and Alzheimer’s disease. Epigenomes 5(2), (2021).
   PubMed Web of Science ®Google Scholar
• Manna S , Mishra J , Baral T et al. Epigenetic signaling and crosstalk in regulation of gene expression and disease progression. Epigenomics doi: 10.2217/epi-2023-0235 (2023).
   PubMed Web of Science ®Google Scholar
• Mir FA , Amanullah A , Jain BP , Hyderi Z , Gautam A . Neuroepigenetics of ageing and neurodegeneration-associated dementia: an updated review. Ageing Res. Rev. doi:10.1016/j.arr.2023.102067 102067 (2023).
   PubMed Web of Science ®Google Scholar
• Basavarajappa BS , Subbanna S . Histone methylation regulation in neurodegenerative disorders. Int. J. Mol. Sci. 22(9), (2021).
   PubMed Web of Science ®Google Scholar
• Li Z , Wang X , Wang X et al. Research progress on the role of extracellular vesicles in neurodegenerative diseases. Transl. Neurodegener. 12(1), 43 (2023).
   PubMed Web of Science ®Google Scholar
• Liang Y , Zhong G , Ren M et al. The role of ubiquitin-proteasome system and mitophagy in the pathogenesis of Parkinson’s disease. Neuromolecular Med. doi: 10.1007/s12017-023-08755-0 (2023).
   PubMed Web of Science ®Google Scholar
• Pinky , Neha , Ali M et al. Unravelling of molecular biomarkers in synaptic plasticity of Alzheimer’s disease: critical role of the restoration of neuronal circuits. Ageing Res. Rev. doi:10.1016/j.arr.2023.102069 102069 (2023).
   PubMed Web of Science ®Google Scholar
• Choudhary C , Kumar C , Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834–840 (2009).
   PubMed Web of Science ®Google Scholar
• Kurdistani SK , Tavazoie S , Grunstein M . Mapping global histone acetylation patterns to gene expression. Cell 117(6), 721–733 (2004).
   PubMed Web of Science ®Google Scholar
• Marmorstein R . Protein modules that manipulate histone tails for chromatin regulation. Nat. Rev. Mol. Cell Biol. 2(6), 422–432 (2001).
   PubMed Web of Science ®Google Scholar
• Allfrey VG , Faulkner R , Mirsky AE . Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA 51(5), 786–794 (1964).
   PubMed Web of Science ®Google Scholar
• Katan-Khaykovich Y , Struhl K . Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. Genes Dev. 16(6), 743–752 (2002).
   PubMed Web of Science ®Google Scholar
• Waterborg JH . Dynamics of histone acetylation in Saccharomyces cerevisiae . Biochemistry 40(8), 2599–2605 (2001).
   PubMed Web of Science ®Google Scholar
• Kurdistani SK , Grunstein M . Histone acetylation and deacetylation in yeast. Nat. Rev. Mol. Cell Biol. 4(4), 276–284 (2003).
   PubMed Web of Science ®Google Scholar
• Verdone L , Caserta M , Di Mauro E . Role of histone acetylation in the control of gene expression. Biochem. Cell Biol. 83(3), 344–353 (2005).
   PubMed Web of Science ®Google Scholar
• Timmermann S , Lehrmann H , Polesskaya A , Harel-Bellan A . Histone acetylation and disease. Cell. Mol. Life Sci. 58(5–6), 728–736 (2001).
   PubMed Web of Science ®Google Scholar
• Salah Ud-Din AI , Tikhomirova A , Roujeinikova A . Structure and functional diversity of GCN5-related N-acetyltransferases (GNAT). Int. J. Mol. Sci. 17(7), (2016).
   Web of Science ®Google Scholar
• Lafon A , Chang CS , Scott EM , Jacobson SJ , Pillus L . MYST opportunities for growth control: yeast genes illuminate human cancer gene functions. Oncogene 26(37), 5373–5384 (2007).
   PubMed Web of Science ®Google Scholar
• Graff J , Tsai LH . The potential of HDAC inhibitors as cognitive enhancers. Annu. Rev. Pharmacol. Toxicol. 53, 311–330 (2013).
   PubMed Web of Science ®Google Scholar
• Laurent L , Wong E , Li G et al. Dynamic changes in the human methylome during differentiation. Genome Res. 20(3), 320–331 (2010).
   PubMed Web of Science ®Google Scholar
• Wang J , Yu JT , Tan MS , Jiang T , Tan L . Epigenetic mechanisms in Alzheimer’s disease: implications for pathogenesis and therapy. Ageing Res. Rev. 12(4), 1024–1041 (2013).
   PubMed Web of Science ®Google Scholar
• Xu K , Dai XL , Huang HC , Jiang ZF . Targeting HDACs: a promising therapy for Alzheimer’s disease. Oxid. Med. Cell Longev. 2011, 143269 (2011).
   PubMed Web of Science ®Google Scholar
• Finnin MS , Donigian JR , Cohen A et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749), 188–193 (1999).
   PubMed Web of Science ®Google Scholar
• Maolanon AR , Madsen AS , Olsen CA . Innovative strategies for selective inhibition of histone deacetylases. Cell Chem. Biol. 23(7), 759–768 (2016).
   PubMed Web of Science ®Google Scholar
• Shukla S , Tekwani BL . Histone deacetylases inhibitors in neurodegenerative diseases, neuroprotection and neuronal differentiation. Front. Pharmacol. 11, 537 (2020).
   PubMed Web of Science ®Google Scholar
• Peixoto L , Abel T . The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology 38(1), 62–76 (2013).
   PubMed Web of Science ®Google Scholar
• Geng H , Chen H , Wang H , Wang L . The histone modifications of neuronal plasticity. Neural Plast. 2021, 6690523 (2021).
   PubMed Web of Science ®Google Scholar
• Lubin FD , Roth TL , Sweatt JD . Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J. Neurosci. 28(42), 10576–10586 (2008).
   PubMed Web of Science ®Google Scholar
• De La Fuente V , Federman N , Fustinana MS , Zalcman G , Romano A . Calcineurin phosphatase as a negative regulator of fear memory in hippocampus: control on nuclear factor-kappaB signaling in consolidation and reconsolidation. Hippocampus 24(12), 1549–1561 (2014).
   PubMed Web of Science ®Google Scholar
• Federman N , De La Fuente V , Zalcman G et al. Nuclear factor kappaB-dependent histone acetylation is specifically involved in persistent forms of memory. J. Neurosci. 33(17), 7603–7614 (2013).
   PubMed Web of Science ®Google Scholar
• Korzus E , Rosenfeld MG , Mayford M . CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42(6), 961–972 (2004).
   PubMed Web of Science ®Google Scholar
• Alarcon JM , Malleret G , Touzani K et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42(6), 947–959 (2004).
   PubMed Web of Science ®Google Scholar
• Wood MA , Kaplan MP , Park A et al. Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn. Mem. 12(2), 111–119 (2005).
   PubMed Web of Science ®Google Scholar
• Slaughter MJ , Shanle EK , Khan A et al. HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell Rep. 34(3), 108638 (2021).
   PubMed Web of Science ®Google Scholar
• Fraga MF , Ballestar E , Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102(30), 10604–10609 (2005).
   PubMed Web of Science ®Google Scholar
• Farris SP , Mayfield RD . Epigenetic and non-coding regulation of alcohol abuse and addiction. Int. Rev. Neurobiol. 156, 63–86 (2021).
   PubMed Web of Science ®Google Scholar
• Lardenoije R , Iatrou A , Kenis G et al. The epigenetics of aging and neurodegeneration. Prog. Neurobiol. 131, 21–64 (2015).
   PubMed Web of Science ®Google Scholar
• Basavarajappa BS , Subbanna S . Epigenetic mechanisms in developmental alcohol-induced neurobehavioral deficits. Brain Sci. 6(2), 12 (2016).
   PubMed Web of Science ®Google Scholar
• Mattson MP , Sherman M . Perturbed signal transduction in neurodegenerative disorders involving aberrant protein aggregation. Neuromolecular Med. 4(1–2), 109–132 (2003).
   PubMed Web of Science ®Google Scholar
• Robakis NK . An Alzheimer’s disease hypothesis based on transcriptional dysregulation. Amyloid 10(2), 80–85 (2003).
   PubMed Web of Science ®Google Scholar
• Yamada T , Yoshiyama Y , Kawaguchi N . Expression of activating transcription factor-2 (ATF-2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non-neurological brain tissues. Brain Res. 749(2), 329–334 (1997).
   PubMed Web of Science ®Google Scholar
• Hai T , Curran T . Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl Acad. Sci. USA 88(9), 3720–3724 (1991).
   PubMed Web of Science ®Google Scholar
• Lee KA , Masson N . Transcriptional regulation by CREB and its relatives. Biochim. Biophys. Acta 1174(3), 221–233 (1993).
   PubMedGoogle Scholar
• Tong L , Thornton PL , Balazs R , Cotman CW . Beta-amyloid-(1–42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J. Biol. Chem. 276(20), 17301–17306 (2001).
   PubMed Web of Science ®Google Scholar
• Vitolo OV , Sant’angelo A , Costanzo V , Battaglia F , Arancio O , Shelanski M . Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl Acad. Sci. USA 99(20), 13217–13221 (2002).
   PubMed Web of Science ®Google Scholar
• Duclot F , Meffre J , Jacquet C , Gongora C , Maurice T . Mice knock out for the histone acetyltransferase p300/CREB binding protein-associated factor develop a resistance to amyloid toxicity. Neuroscience 167(3), 850–863 (2010).
   PubMed Web of Science ®Google Scholar
• Park SY , Kim MJ , Kim YJ et al. Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-kappaB-mediated neuroinflammation induced by Abeta in a model of Alzheimer’s disease. Int. J. Mol. Med. 35(4), 1109–1118 (2015).
   PubMed Web of Science ®Google Scholar
• Creighton SD , Jardine KH , Desimone A et al. Age-dependent attenuation of spatial memory deficits by the histone acetyltransferase p300/CBP-associated factor (PCAF) in 3xTG Alzheimer’s disease mice. Learn. Mem. 29(3), 71–76 (2022).
   PubMed Web of Science ®Google Scholar
• Espana J , Valero J , Minano-Molina AJ et al. Beta-amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1. J. Neurosci. 30(28), 9402–9410 (2010).
   PubMed Web of Science ®Google Scholar
• Caccamo A , Maldonado MA , Bokov AF , Majumder S , Oddo S . CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 107(52), 22687–22692 (2010).
   PubMed Web of Science ®Google Scholar
• Saha RN , Ghosh A , Palencia CA , Fung YK , Dudek SM , Pahan K . TNF-alpha preconditioning protects neurons via neuron-specific up-regulation of CREB-binding protein. J. Immunol. 183(3), 2068–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Saura CA , Choi SY , Beglopoulos V et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42(1), 23–36 (2004).
   PubMed Web of Science ®Google Scholar
• Federman N , Fustinana MS , Romano A . Histone acetylation is recruited in consolidation as a molecular feature of stronger memories. Learn. Mem. 16(10), 600–606 (2009).
   PubMed Web of Science ®Google Scholar
• Wang YJ , Okutani F , Murata Y , Taniguchi M , Namba T , Kaba H . Histone acetylation in the olfactory bulb of young rats facilitates aversive olfactory learning and synaptic plasticity. Neuroscience 232, 21–31 (2013).
   PubMed Web of Science ®Google Scholar
• Levenson JM , O’Riordan KJ , Brown KD , Trinh MA , Molfese DL , Sweatt JD . Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279(39), 40545–40559 (2004).
   PubMed Web of Science ®Google Scholar
• Vecsey CG , Hawk JD , Lattal KM et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 27(23), 6128–6140 (2007).
   PubMed Web of Science ®Google Scholar
• Roth SY , Denu JM , Allis CD . Histone acetyltransferases. Annu. Rev. Biochem. 70, 81–120 (2001).
   PubMed Web of Science ®Google Scholar
• Guan JS , Haggarty SJ , Giacometti E et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243), 55–60 (2009).
   PubMed Web of Science ®Google Scholar
• Bredy TW , Wu H , Crego C , Zellhoefer J , Sun YE , Barad M . Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn. Mem. 14(4), 268–276 (2007).
   PubMed Web of Science ®Google Scholar
• Ding H , Dolan PJ , Johnson GV . Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 106(5), 2119–2130 (2008).
   PubMed Web of Science ®Google Scholar
• Francis YI , Fa M , Ashraf H et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer’s disease. J. Alzheimers Dis. 18(1), 131–139 (2009).
   PubMed Web of Science ®Google Scholar
• Majid T , Griffin D , Criss Z 2nd , Jarpe M , Pautler RG . Pharmacologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer’s disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice. Alzheimers Dement. (NY) 1(3), 170–181 (2015).
   PubMedGoogle Scholar
• Fan SJ , Huang FI , Liou JP , Yang CR . The novel histone deacetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model. Cell Death Dis. 9(6), 655 (2018).
   PubMedGoogle Scholar
• Kilgore M , Miller CA , Fass DM et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 35(4), 870–880 (2010).
   PubMed Web of Science ®Google Scholar
• Ricobaraza A , Cuadrado-Tejedor M , Marco S , Perez-Otano I , Garcia-Osta A . Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22(5), 1040–1050 (2012).
   PubMed Web of Science ®Google Scholar
• Govindarajan N , Agis-Balboa RC , Walter J , Sananbenesi F , Fischer A . Sodium butyrate improves memory function in an Alzheimer’s disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 26(1), 187–197 (2011).
   PubMed Web of Science ®Google Scholar
• Cuadrado-Tejedor M , Ricobaraza AL , Torrijo R , Franco R , Garcia-Osta A . Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer’s disease-like phenotype of a commonly used mouse model. Curr. Pharm. Des. 19(28), 5076–5084 (2013).
   PubMed Web of Science ®Google Scholar
• Ricobaraza A , Cuadrado-Tejedor M , Garcia-Osta A . Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Abeta. Front. Biosci. (Elite Ed.) 3(4), 1375–1384 (2011).
   PubMedGoogle Scholar
• Cao T , Zhou X , Zheng X et al. Histone deacetylase inhibitor alleviates the neurodegenerative phenotypes and histone dysregulation in presenilins-deficient mice. Front. Aging Neurosci. 10, 137 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang K , Schrag M , Crofton A , Trivedi R , Vinters H , Kirsch W . Targeted proteomics for quantification of histone acetylation in Alzheimer’s disease. Proteomics 12(8), 1261–1268 (2012).
   PubMed Web of Science ®Google Scholar
• Graff J , Rei D , Guan JS et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483(7388), 222–226 (2012).
   PubMed Web of Science ®Google Scholar
• Holtzman DM , Morris JC , Goate AM . Alzheimer’s disease: the challenge of the second century. Sci. Transl. Med. 3(77), 77sr71 (2011).
   Web of Science ®Google Scholar
• Frankland PW , Bontempi B . The organization of recent and remote memories. Nat. Rev. Neurosci. 6(2), 119–130 (2005).
   PubMed Web of Science ®Google Scholar
• Walker MP , Laferla FM , Oddo SS , Brewer GJ . Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer’s disease. Age (Dordr.) 35(3), 519–531 (2013).
   PubMed Web of Science ®Google Scholar
• Narayan PJ , Lill C , Faull R , Curtis MA , Dragunow M . Increased acetyl and total histone levels in post-mortem Alzheimer’s disease brain. Neurobiol. Dis. 74, 281–294 (2015).
   PubMed Web of Science ®Google Scholar
• Janczura KJ , Volmar CH , Sartor GC et al. Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model. Proc. Natl Acad. Sci. USA 115(47), E11148–E11157 (2018).
   PubMed Web of Science ®Google Scholar
• Yao ZG , Liang L , Liu Y et al. Valproate improves memory deficits in an Alzheimer’s disease mouse model: investigation of possible mechanisms of action. Cell. Mol. Neurobiol. 34(6), 805–812 (2014).
   PubMed Web of Science ®Google Scholar
• Xuan AG , Pan XB , Wei P et al. Valproic acid alleviates memory deficits and attenuates amyloid-beta deposition in transgenic mouse model of Alzheimer’s disease. Mol. Neurobiol. 51(1), 300–312 (2015).
   PubMed Web of Science ®Google Scholar
• Wang C , Shen D , Hu Y et al. Selective targeting of class I HDAC reduces microglial inflammation in the entorhinal cortex of young APP/PS1 mice. Int. J. Mol. Sci. 24(5), (2023).
   Web of Science ®Google Scholar
• Santana DA , Bedrat A , Puga RD et al. The role of H3K9 acetylation and gene expression in different brain regions of Alzheimer’s disease patients. Epigenomics 14(11), 651–670 (2022).
   PubMed Web of Science ®Google Scholar
• Ramamurthy E , Welch G , Cheng J et al. Cell type-specific histone acetylation profiling of Alzheimer’s disease subjects and integration with genetics. Front. Mol. Neurosci. 15, 948456 (2022).
   PubMed Web of Science ®Google Scholar
• Kropf E , Fahnestock M . Effects of reactive oxygen and nitrogen species on TrkA expression and signalling: implications for proNGF in aging and Alzheimer’s disease. Cells 10(8), (2021).
   PubMed Web of Science ®Google Scholar
• Jiang Y , Alam JJ , Gomperts SN et al. Preclinical and randomized clinical evaluation of the p38alpha kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nat. Commun. 13(1), 5308 (2022).
   PubMed Web of Science ®Google Scholar
• Pensalfini A , Kim S , Subbanna S et al. Endosomal dysfunction induced by directly overactivating Rab5 recapitulates prodromal and neurodegenerative features of Alzheimer’s disease. Cell Rep. 33(8), 108420 (2020).
   PubMed Web of Science ®Google Scholar
• Li X , Zhan Z , Zhang J , Zhou F , An L . Beta-hydroxybutyrate ameliorates Abeta-induced downregulation of TrkA expression by inhibiting HDAC1/3 in SH-SY5Y cells. Am J. Alzheimers Dis. Other Demen. 35, 1533317519883496 (2020).
   Web of Science ®Google Scholar
• Schueller E , Paiva I , Blanc F et al. Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer’s disease patients. Eur. Neuropsychopharmacol. 33, 101–116 (2020).
   PubMed Web of Science ®Google Scholar
• Cai HB , Fan ZZ , Tian T et al. Diabetes-induced H3K9 hyperacetylation promotes development of Alzheimer’s disease through CDK5. J. Alzheimers Dis. 77(1), 75–84 (2020).
   PubMed Web of Science ®Google Scholar
• Klein HU , Mccabe C , Gjoneska E et al. Epigenome-wide study uncovers large-scale changes in histone acetylation driven by tau pathology in aging and Alzheimer’s human brains. Nat. Neurosci. 22(1), 37–46 (2019).
   PubMed Web of Science ®Google Scholar
• Rustenhoven J , Smith AM , Smyth LC et al. PU.1 regulates Alzheimer’s disease-associated genes in primary human microglia. Mol. Neurodegener. 13(1), 44 (2018).
   PubMedGoogle Scholar
• Huang KL , Marcora E , Pimenova AA et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat. Neurosci. 20(8), 1052–1061 (2017).
   PubMed Web of Science ®Google Scholar
• Ralvenius WT , Mungenast AE , Woolf H et al. A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation. J. Exp. Med. 220(11), (2023).
   PubMed Web of Science ®Google Scholar
• Patel PJ , Ren Y , Yan Z . Epigenomic analysis of Alzheimer’s disease brains reveals diminished CTCF binding on genes involved in synaptic organization. Neurobio. Dis. 184, 106192 (2023).
   PubMed Web of Science ®Google Scholar
• Denninger JW , Marletta MA . Guanylate cyclase and the NO/cGMP signaling pathway. Biochim. Biophys. Acta 1411(2–3), 334–350 (1999).
   PubMed Web of Science ®Google Scholar
• Tropea MR , Gulisano W , Vacanti V , Arancio O , Puzzo D , Palmeri A . Nitric oxide/cGMP/CREB pathway and amyloid-beta crosstalk: from physiology to Alzheimer’s disease. Free Radic. Biol. Med. 193(Pt 2), 657–668 (2022).
   PubMedGoogle Scholar
• Fiorito J , Saeed F , Zhang H et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 60, 285–294 (2013).
   PubMed Web of Science ®Google Scholar
• Puzzo D , Staniszewski A , Deng SX et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer’s disease mouse model. J. Neurosci. 29(25), 8075–8086 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang J , Guo J , Zhao X et al. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav. Brain Res. 250, 230–237 (2013).
   PubMed Web of Science ®Google Scholar
• Cuadrado-Tejedor M , Garcia-Barroso C , Sanzhez-Arias J et al. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease. Clin. Epigenetics 7, 108 (2015).
   PubMed Web of Science ®Google Scholar
• Platenik J , Fisar Z , Buchal R et al. GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer’s disease and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 50, 83–93 (2014).
   PubMed Web of Science ®Google Scholar
• Cuadrado-Tejedor M , Garcia-Barroso C , Sanchez-Arias JA et al. A first-in-class small-molecule that acts as a dual inhibitor of HDAC and PDE5 and that rescues hippocampal synaptic impairment in Alzheimer’s disease mice. Neuropsychopharmacology 42(2), 524–539 (2017).
   PubMed Web of Science ®Google Scholar
• Pirooznia SK , Sarthi J , Johnson AA et al. Tip60 HAT activity mediates APP induced lethality and apoptotic cell death in the CNS of a Drosophila Alzheimer’s disease model. PLOS ONE 7(7), e41776 (2012).
   PubMed Web of Science ®Google Scholar
• Pirooznia SK , Chiu K , Chan MT , Zimmerman JE , Elefant F . Epigenetic regulation of axonal growth of Drosophila pacemaker cells by histone acetyltransferase tip60 controls sleep. Genetics 192(4), 1327–1345 (2012).
   PubMed Web of Science ®Google Scholar
• Xu S , Wilf R , Menon T , Panikker P , Sarthi J , Elefant F . Epigenetic control of learning and memory in Drosophila by Tip60 HAT action. Genetics 198(4), 1571–1586 (2014).
   PubMed Web of Science ®Google Scholar
• Beaver M , Karisetty BC , Zhang H et al. Chromatin and transcriptomic profiling uncover dysregulation of the Tip60 HAT/HDAC2 epigenomic landscape in the neurodegenerative brain. Epigenetics 17(7), 786–807 (2022).
   PubMedGoogle Scholar
• Panikker P , Xu SJ , Zhang H et al. Restoring Tip60 HAT/HDAC2 balance in the neurodegenerative brain relieves epigenetic transcriptional repression and reinstates cognition. J. Neurosci. 38(19), 4569–4583 (2018).
   PubMed Web of Science ®Google Scholar
• Rabal O , Sanchez-Arias JA , Cuadrado-Tejedor M et al. Multitarget approach for the treatment of Alzheimer’s disease: inhibition of phosphodiesterase 9 (PDE9) and histone deacetylases (HDACs) covering diverse selectivity profiles. ACS Chem. Neurosci. 10(9), 4076–4101 (2019).
   PubMed Web of Science ®Google Scholar
• Cuadrado-Tejedor M , Perez-Gonzalez M , Garcia-Munoz C et al. Taking advantage of the selectivity of histone deacetylases and phosphodiesterase inhibitors to design better therapeutic strategies to treat Alzheimer’s disease. Front. Aging Neurosci. 11, 149 (2019).
   PubMed Web of Science ®Google Scholar
• Trzeciakiewicz H , Ajit D , Tseng JH et al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat. Commun. 11(1), 5522 (2020).
   PubMed Web of Science ®Google Scholar
• Patnaik D , Pao PC , Zhao WN et al. Exifone is a potent HDAC1 activator with neuroprotective activity in human neuronal models of neurodegeneration. ACS Chem. Neurosci. 12(2), 271–284 (2021).
   PubMed Web of Science ®Google Scholar
• Lang AE , Obeso JA . Time to move beyond nigrostriatal dopamine deficiency in Parkinson’s disease. Ann. Neurol. 55(6), 761–765 (2004).
   PubMed Web of Science ®Google Scholar
• Obeso JA , Stamelou M , Goetz CG et al. Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the shaking palsy. Mov. Disord. 32(9), 1264–1310 (2017).
   PubMed Web of Science ®Google Scholar
• Burke RE , O’Malley K . Axon degeneration in Parkinson’s disease. Exp. Neurol. 246, 72–83 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng HC , Ulane CM , Burke RE . Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67(6), 715–725 (2010).
   PubMed Web of Science ®Google Scholar
• Lang AE . A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov. Disord. 26(5), 775–783 (2011).
   PubMed Web of Science ®Google Scholar
• Dauer W , Przedborski S . Parkinson’s disease: mechanisms and models. Neuron 39(6), 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Bandres-Ciga S , Diez-Fairen M , Kim JJ , Singleton AB . Genetics of Parkinson’s disease: an introspection of its journey towards precision medicine. Neurobiol. Dis. 137, 104782 (2020).
   PubMed Web of Science ®Google Scholar
• Dulski J , Uitti RJ , Ross OA , Wszolek ZK . Genetic architecture of Parkinson’s disease subtypes–review of the literature. Front. Aging Neurosci. 14, 1023574 (2022).
   PubMed Web of Science ®Google Scholar
• Funayama M , Nishioka K , Li Y , Hattori N . Molecular genetics of Parkinson’s disease: contributions and global trends. J. Hum. Genet. 68(3), 125–130 (2023).
   PubMed Web of Science ®Google Scholar
• Li B , Zhao G , Zhou Q et al. Gene4PD: a comprehensive genetic database of Parkinson’s disease. Front. Neurosci. 15, 679568 (2021).
   PubMed Web of Science ®Google Scholar
• Nalls MA , Pankratz N , Lill CM et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46(9), 989–993 (2014).
   PubMed Web of Science ®Google Scholar
• Muller-Nedebock AC , Dekker MCJ , Farrer MJ et al. Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease. NPJ Parkinsons Dis. 9(1), 110 (2023).
   PubMed Web of Science ®Google Scholar
• Goldman SM , Marek K , Ottman R et al. Concordance for Parkinson’s disease in twins: a 20-year update. Ann. Neurol. 85(4), 600–605 (2019).
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K , Gatz M , Reynolds CA , Prescott CA , Pedersen NL . Heritability of Parkinson disease in Swedish twins: a longitudinal study. Neurobiol. Aging 32(10), 1923–1928 (2011).
   Web of Science ®Google Scholar
• Bjorklund G , Stejskal V , Urbina MA , Dadar M , Chirumbolo S , Mutter J . Metals and Parkinson’s disease: mechanisms and biochemical processes. Curr. Med. Chem. 25(19), 2198–2214 (2018).
   PubMed Web of Science ®Google Scholar
• Hsu YC , Chang CW , Lee HL et al. Association between history of dental amalgam fillings and risk of Parkinson’s disease: a population-based retrospective cohort study in Taiwan. PLOS ONE 11(12), e0166552 (2016).
   PubMed Web of Science ®Google Scholar
• Pamphlett R , Bishop DP . Mercury is present in neurons and oligodendrocytes in regions of the brain affected by Parkinson’s disease and co-localises with Lewy bodies. PLOS ONE 17(1), e0262464 (2022).
   PubMed Web of Science ®Google Scholar
• Willis AW , Evanoff BA , Lian M et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am. J. Epidemiol. 172(12), 1357–1363 (2010).
   PubMed Web of Science ®Google Scholar
• GBDPSD Collaborators . Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17(11), 939–953 (2018).
   PubMed Web of Science ®Google Scholar
• Breen DP , Michell AW , Barker RA . Parkinson’s disease–the continuing search for biomarkers. Clin. Chem. Lab. Med. 49(3), 393–401 (2011).
   PubMed Web of Science ®Google Scholar
• Peng C , Trojanowski JQ , Lee VM . Protein transmission in neurodegenerative disease. Nat. Rev. Neurol. 16(4), 199–212 (2020).
   PubMed Web of Science ®Google Scholar
• Mezzaroba L , Alfieri DF , Colado Simao AN , Vissoci Reiche EM . The role of zinc, copper, manganese and iron in neurodegenerative diseases. Neurotoxicology 74, 230–241 (2019).
   PubMed Web of Science ®Google Scholar
• Puspita L , Chung SY , Shim JW . Oxidative stress and cellular pathologies in Parkinson’s disease. Mol. Brain 10(1), 53 (2017).
   PubMed Web of Science ®Google Scholar
• Przedborski S . The two-century journey of Parkinson disease research. Nat. Rev. Neurosci. 18(4), 251–259 (2017).
   PubMed Web of Science ®Google Scholar
• Abeliovich A , Gitler AD . Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 539(7628), 207–216 (2016).
   PubMed Web of Science ®Google Scholar
• Ammal Kaidery N , Tarannum S , Thomas B . Epigenetic landscape of Parkinson’s disease: emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics 10(4), 698–708 (2013).
   PubMed Web of Science ®Google Scholar
• Kontopoulos E , Parvin JD , Feany MB . Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15(20), 3012–3023 (2006).
   PubMed Web of Science ®Google Scholar
• Gardian G , Yang L , Cleren C , Calingasan NY , Klivenyi P , Beal MF . Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med. 5(3), 235–241 (2004).
   PubMed Web of Science ®Google Scholar
• Chen PS , Peng GS , Li G et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11(12), 1116–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Wu X , Chen PS , Dallas S et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 11(8), 1123–1134 (2008).
   PubMed Web of Science ®Google Scholar
• Airaksinen MS , Saarma M . The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3(5), 383–394 (2002).
   PubMed Web of Science ®Google Scholar
• Choong CJ , Sasaki T , Hayakawa H et al. A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson’s disease. Neurobiol. Aging 37, 103–116 (2016).
   PubMed Web of Science ®Google Scholar
• Hegarty SV , O’Leary E , Solger F , Stanicka J , Sullivan AM , O’Keeffe GW . A small molecule activator of p300/CBP histone acetyltransferase promotes survival and neurite growth in a cellular model of Parkinson’s disease. Neurotox. Res. 30(3), 510–520 (2016).
   PubMed Web of Science ®Google Scholar
• Hegarty SV , O’Keeffe GW , Sullivan AM . Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson’s disease. Neural Regen. Res. 9(19), 1708–1711 (2014).
   PubMed Web of Science ®Google Scholar
• Outeiro TF , Kontopoulos E , Altmann SM et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science 317(5837), 516–519 (2007).
   PubMed Web of Science ®Google Scholar
• Kanthasamy A , Jin H , Anantharam V et al. Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology 33(4), 833–837 (2012).
   PubMed Web of Science ®Google Scholar
• Song C , Kanthasamy A , Anantharam V , Sun F , Kanthasamy AG . Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol. Pharmacol. 77(4), 621–632 (2010).
   PubMed Web of Science ®Google Scholar
• Song C , Kanthasamy A , Jin H , Anantharam V , Kanthasamy AG . Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. Neurotoxicology 32(5), 586–595 (2011).
   PubMed Web of Science ®Google Scholar
• Chen S , Bellew C , Yao X et al. Histone deacetylase (HDAC) activity is critical for embryonic kidney gene expression, growth, and differentiation. J. Biol. Chem. 286(37), 32775–32789 (2011).
   PubMed Web of Science ®Google Scholar
• Van Heesbeen HJ , Smidt MP . Entanglement of genetics and epigenetics in Parkinson’s disease. Front. Neurosci. 13, 277 (2019).
   PubMed Web of Science ®Google Scholar
• Toker L , Tran GT , Sundaresan J et al. Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain. Mol. Neurodegener. 16(1), 31 (2021).
   PubMed Web of Science ®Google Scholar
• Nicholas AP , Lubin FD , Hallett PJ et al. Striatal histone modifications in models of levodopa-induced dyskinesia. J. Neurochem. 106(1), 486–494 (2008).
   PubMed Web of Science ®Google Scholar
• Patel VP , Chu CT . Decreased SIRT2 activity leads to altered microtubule dynamics in oxidatively-stressed neuronal cells: implications for Parkinson’s disease. Exp. Neurol. 257, 170–181 (2014).
   PubMed Web of Science ®Google Scholar
• Chiu S , Terpstra KJ , Bureau Y et al. Liposomal-formulated curcumin [Lipocurc] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson’s disease: implications for epigenetics-based nanotechnology-driven drug platform. J. Complement. Integr. Med. 10, 75–88 (2013).
   Google Scholar
• Sharma S , Taliyan R , Singh S . Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav. Brain Res. 291, 306–314 (2015).
   PubMed Web of Science ®Google Scholar
• St Laurent R , O’Brien LM , Ahmad ST . Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson’s disease. Neuroscience 246, 382–390 (2013).
   PubMed Web of Science ®Google Scholar
• Liu J , Wang F , Liu S et al. Sodium butyrate exerts protective effect against Parkinson’s disease in mice via stimulation of glucagon like peptide-1. J. Neurol. Sci. 381, 176–181 (2017).
   PubMed Web of Science ®Google Scholar
• Paiva I , Pinho R , Pavlou MA et al. Sodium butyrate rescues dopaminergic cells from alpha-synuclein-induced transcriptional deregulation and DNA damage. Hum. Mol. Genet. 26(12), 2231–2246 (2017).
   PubMed Web of Science ®Google Scholar
• Zhou W , Bercury K , Cummiskey J , Luong N , Lebin J , Freed CR . Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem. 286(17), 14941–14951 (2011).
   PubMed Web of Science ®Google Scholar
• Roy A , Ghosh A , Jana A et al. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson’s disease. PLOS ONE 7(6), e38113 (2012).
   PubMed Web of Science ®Google Scholar
• Chen SH , Wu HM , Ossola B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol. 165(2), 494–505 (2012).
   PubMed Web of Science ®Google Scholar
• Kidd SK , Schneider JS . Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 1354, 172–178 (2010).
   PubMed Web of Science ®Google Scholar
• Suo H , Wang P , Tong J et al. NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of Parkinson’s disease. Neuropharmacology 99, 67–78 (2015).
   PubMed Web of Science ®Google Scholar
• Monti B , Gatta V , Piretti F , Raffaelli SS , Virgili M , Contestabile A . Valproic acid is neuroprotective in the rotenone rat model of Parkinson’s disease: involvement of alpha-synuclein. Neurotox. Res. 17(2), 130–141 (2010).
   PubMed Web of Science ®Google Scholar
• Kidd SK , Schneider JS . Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience 194, 189–194 (2011).
   PubMed Web of Science ®Google Scholar
• Pan T , Li X , Xie W , Jankovic J , Le W . Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 579(30), 6716–6720 (2005).
   PubMed Web of Science ®Google Scholar
• Khan N , Jeffers M , Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409(2), 581–589 (2008).
   PubMed Web of Science ®Google Scholar
• Kim T , Song S , Park Y , Kang S , Seo H . HDAC inhibition by valproic acid induces neuroprotection and improvement of PD-like behaviors in LRRK2 R1441G transgenic mice. Exp. Neurobiol. 28(4), 504–515 (2019).
   PubMed Web of Science ®Google Scholar
• Mazzocchi M , Goulding SR , Wyatt SL , Collins LM , Sullivan AM , O’Keeffe GW . LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and alpha-synuclein-induced degeneration in cellular models of Parkinson’s disease. Mol. Cell. Neurosci. 115, 103642 (2021).
   PubMed Web of Science ®Google Scholar
• Mazzocchi M , Goulding SR , Morales-Prieto N et al. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson’s disease. Brain Behav. Immun. 102, 151–160 (2022).
   PubMed Web of Science ®Google Scholar
• Harrison IF , Smith AD , Dexter DT . Pathological histone acetylation in Parkinson’s disease: neuroprotection and inhibition of microglial activation through SIRT 2 inhibition. Neurosci. Lett. 666, 48–57 (2018).
   PubMed Web of Science ®Google Scholar
• Guan Q , Wang M , Chen H , Yang L , Yan Z , Wang X . Aging-related 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurochemical and behavioral deficits and redox dysfunction: improvement by AK-7. Exp. Gerontol. 82, 19–29 (2016).
   PubMed Web of Science ®Google Scholar
• Wang Y , Xu H , Fu Q , Ma R , Xiang J . Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in Parkinsonian rats. J. Neurol. Sci. 304(1–2), 29–34 (2011).
   PubMed Web of Science ®Google Scholar
• Blanchet J , Longpre F , Bureau G et al. Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(5), 1243–1250 (2008).
   PubMed Web of Science ®Google Scholar
• Albani D , Polito L , Batelli S et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1–42) peptide. J. Neurochem. 110(5), 1445–1456 (2009).
   PubMed Web of Science ®Google Scholar
• Lee MK , Kang SJ , Poncz M , Song KJ , Park KS . Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp. Mol. Med. 39(3), 376–384 (2007).
   PubMed Web of Science ®Google Scholar
• Bournival J , Quessy P , Martinoli MG . Protective effects of resveratrol and quercetin against MPP+-induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell. Mol. Neurobiol. 29(8), 1169–1180 (2009).
   PubMed Web of Science ®Google Scholar
• Lin TK , Chen SD , Chuang YC et al. Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int. J. Mol. Sci. 15(1), 1625–1646 (2014).
   PubMed Web of Science ®Google Scholar
• Chen HH , Chang PC , Chen C , Chan MH . Protective and therapeutic activity of honokiol in reversing motor deficits and neuronal degeneration in the mouse model of Parkinson’s disease. Pharmacol. Rep. 70(4), 668–676 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang S , Ma Y , Feng J . Neuroprotective mechanisms of epsilon-viniferin in a rotenone-induced cell model of Parkinson’s disease: significance of SIRT3-mediated FOXO3 deacetylation. Neural Regen. Res. 15(11), 2143–2153 (2020).
   PubMed Web of Science ®Google Scholar
• Pinho BR , Reis SD , Guedes-Dias P et al. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: therapeutic implications for Parkinson’s disease. Pharmacol. Res. 103, 328–339 (2016).
   PubMed Web of Science ®Google Scholar
• Park G , Tan J , Garcia G , Kang Y , Salvesen G , Zhang Z . Regulation of histone acetylation by autophagy in Parkinson disease. J. Biol. Chem. 291(7), 3531–3540 (2016).
   PubMed Web of Science ®Google Scholar
• Choi HK , Choi Y , Kang H et al. PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death. Hum. Mol. Genet. 24(4), 1127–1141 (2015).
   PubMed Web of Science ®Google Scholar
• Wu Q , Yang X , Zhang L , Zhang Y , Feng L . Nuclear accumulation of histone deacetylase 4 (HDAC4) exerts neurotoxicity in models of Parkinson’s disease. Mol. Neurobiol. 54(9), 6970–6983 (2017).
   PubMed Web of Science ®Google Scholar
• Lang C , Campbell KR , Ryan BJ et al. Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes. Cell Stem Cell 24(1), 93–106e106 (2019).
   PubMed Web of Science ®Google Scholar
• Hourani M , Berretta R , Mendes A , Moscato P . Genetic signatures for a rodent model of Parkinson’s disease using combinatorial optimization methods. Methods Mol. Biol. 453, 379–392 (2008).
   PubMedGoogle Scholar
• Collins LM , Adriaanse LJ , Theratile SD , Hegarty SV , Sullivan AM , O’Keeffe GW . Class-IIa histone deacetylase inhibition promotes the growth of neural processes and protects them against neurotoxic insult. Mol. Neurobiol. 51(3), 1432–1442 (2015).
   PubMed Web of Science ®Google Scholar
• Mazzocchi M , Wyatt SL , Mercatelli D et al. Gene co-expression analysis identifies histone deacetylase 5 and 9 expression in midbrain dopamine neurons and as regulators of neurite growth via bone morphogenetic protein signaling. Front. Cell. Dev. Biol. 7, 191 (2019).
   PubMed Web of Science ®Google Scholar
• Pandey UB , Nie Z , Batlevi Y et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447(7146), 859–863 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alegre P . Recent advances in molecular therapies for neurological disease: triplet repeat disorders. Hum. Mol. Genet. 28(R1), R80–R87 (2019).
   PubMed Web of Science ®Google Scholar
• Nopoulos PC . Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin. Neurosci. 18(1), 91–98 (2016).
   PubMed Web of Science ®Google Scholar
• Paulson H . Repeat expansion diseases. Handb. Clin. Neurol. 147, 105–123 (2018).
   PubMedGoogle Scholar
• Jimenez-Sanchez M , Licitra F , Underwood BR , Rubinsztein DC . Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb. Perspect. Med. 7(7), a024240 (2017).
   PubMed Web of Science ®Google Scholar
• Novak MJ , Tabrizi SJ . Huntington’s disease. BMJ 340, c3109 (2010).
   PubMedGoogle Scholar
• Bassi S , Tripathi T , Monziani A , Di Leva F , Biagioli M . Epigenetics of Huntington’s disease. Adv. Exp. Med. Biol. 978, 277–299 (2017).
   PubMed Web of Science ®Google Scholar
• Wang F , Fischhaber PL , Guo C , Tang TS . Epigenetic modifications as novel therapeutic targets for Huntington’s disease. Epigenomics 6(3), 287–297 (2014).
   PubMed Web of Science ®Google Scholar
• Kim SH , Thomas CA , Andre VM et al. Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro. 3(3), e00060 (2011).
   PubMed Web of Science ®Google Scholar
• Landles C , Bates GP . Huntingtin and the molecular pathogenesis of Huntington’s disease. Fourth in molecular medicine review series. EMBO Rep. 5(10), 958–963 (2004).
   PubMed Web of Science ®Google Scholar
• Becanovic K , Pouladi MA , Lim RS et al. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum. Mol. Genet. 19(8), 1438–1452 (2010).
   PubMed Web of Science ®Google Scholar
• Malla B , Guo X , Senger G , Chasapopoulou Z , Yildirim F . A systematic review of transcriptional dysregulation in Huntington’s disease studied by RNA sequencing. Front. Genet. 12, 751033 (2021).
   PubMed Web of Science ®Google Scholar
• Ferrante RJ , Kubilus JK , Lee J et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J. Neurosci. 23(28), 9418–9427 (2003).
   PubMed Web of Science ®Google Scholar
• Gardian G , Browne SE , Choi DK et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington’s disease. J. Biol. Chem. 280(1), 556–563 (2005).
   PubMed Web of Science ®Google Scholar
• Mcfarland KN , Das S , Sun TT et al. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington’s disease. PLOS ONE 7(7), e41423 (2012).
   PubMed Web of Science ®Google Scholar
• Valor LM , Guiretti D . What’s wrong with epigenetics in Huntington’s disease? Neuropharmacology 80, 103–114 (2014).
   PubMed Web of Science ®Google Scholar
• Yeh HH , Young D , Gelovani JG et al. Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington’s disease. Brain Res. 1504, 16–24 (2013).
   PubMed Web of Science ®Google Scholar
• Sadri-Vakili G , Bouzou B , Benn CL et al. Histones associated with downregulated genes are hypo-acetylated in Huntington’s disease models. Hum. Mol. Genet. 16(11), 1293–1306 (2007).
   PubMed Web of Science ®Google Scholar
• Han H , Cho JW , Lee S et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 46(D1), D380–D386 (2018).
   PubMed Web of Science ®Google Scholar
• Sasi M , Vignoli B , Canossa M , Blum R . Neurobiology of local and intercellular BDNF signaling. Pflugers Arch. 469(5–6), 593–610 (2017).
   PubMed Web of Science ®Google Scholar
• Nucifora FC Jr , Sasaki M , Peters MF et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512), 2423–2428 (2001).
   PubMed Web of Science ®Google Scholar
• Steffan JS , Kazantsev A , Spasic-Boskovic O et al. The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97(12), 6763–6768 (2000).
   PubMed Web of Science ®Google Scholar
• Paldino E , Cardinale A , D’Angelo V , Sauve I , Giampa C , Fusco FR . Selective sparing of striatal interneurons after poly (ADP-ribose) polymerase 1 inhibition in the R6/2 mouse model of Huntington’s disease. Front. Neuroanat. 11, 61 (2017).
   PubMed Web of Science ®Google Scholar
• Jiang H , Nucifora FC Jr , Ross CA , Defranco DB . Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet. 12(1), 1–12 (2003).
   PubMed Web of Science ®Google Scholar
• Kazantsev A , Preisinger E , Dranovsky A , Goldgaber D , Housman D . Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA 96(20), 11404–11409 (1999).
   PubMed Web of Science ®Google Scholar
• Cong SY , Pepers BA , Evert BO et al. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol. Cell. Neurosci. 30(1), 12–23 (2005).
   PubMed Web of Science ®Google Scholar
• Steffan JS , Bodai L , Pallos J et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila . Nature 413(6857), 739–743 (2001).
   PubMed Web of Science ®Google Scholar
• Igarashi S , Morita H , Bennett KM et al. Inducible PC12 cell model of Huntington’s disease shows toxicity and decreased histone acetylation. Neuroreport 14(4), 565–568 (2003).
   PubMed Web of Science ®Google Scholar
• Hockly E , Richon VM , Woodman B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc. Natl Acad. Sci. USA 100(4), 2041–2046 (2003).
   PubMed Web of Science ®Google Scholar
• Mielcarek M , Benn CL , Franklin SA et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington’s disease. PLOS ONE 6(11), e27746 (2011).
   PubMed Web of Science ®Google Scholar
• Quinti L , Chopra V , Rotili D et al. Evaluation of histone deacetylases as drug targets in Huntington’s disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model. PLoS Curr. 2, 1–42 (2010).
   Google Scholar
• Hoshino M , Tagawa K , Okuda T et al. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein. J. Neurochem. 87(1), 257–267 (2003).
   PubMed Web of Science ®Google Scholar
• Oliveira JM , Chen S , Almeida S et al. Mitochondrial-dependent Ca2+ handling in Huntington’s disease striatal cells: effect of histone deacetylase inhibitors. J. Neurosci. 26(43), 11174–11186 (2006).
   PubMed Web of Science ®Google Scholar
• Jia H , Pallos J , Jacques V et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington’s disease. Neurobiol. Dis. 46(2), 351–361 (2012).
   PubMed Web of Science ®Google Scholar
• Hecklau K , Mueller S , Koch SP et al. The effects of selective inhibition of histone deacetylase 1 and 3 in Huntington’s disease mice. Front. Mol. Neurosci. 14, 616886 (2021).
   PubMed Web of Science ®Google Scholar
• Thomas EA , Coppola G , Desplats PA et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice. Proc. Natl Acad. Sci. USA 105(40), 15564–15569 (2008).
   PubMed Web of Science ®Google Scholar
• Jia H , Kast RJ , Steffan JS , Thomas EA . Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington’s disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 21(24), 5280–5293 (2012).
   PubMed Web of Science ®Google Scholar
• Mielcarek M , Landles C , Weiss A et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 11(11), e1001717 (2013).
   PubMed Web of Science ®Google Scholar
• Macabuag N , Esmieu W , Breccia P et al. Developing HDAC4-selective protein degraders to investigate the role of HDAC4 in Huntington’s disease pathology. J. Med. Chem. 65(18), 12445–12459 (2022).
   PubMed Web of Science ®Google Scholar
• Federspiel JD , Greco TM , Lum KK , Cristea IM . HDAC4 interactions in Huntington’s disease viewed through the prism of multiomics. Mol. Cell. Proteomics 18(1 Suppl. 8), S92–S113 (2019).
   PubMed Web of Science ®Google Scholar
• Mano T , Suzuki T , Tsuji S , Iwata A . Differential effect of HDAC3 on cytoplasmic and nuclear huntingtin aggregates. PLOS ONE 9(11), e111277 (2014).
   PubMed Web of Science ®Google Scholar
• Chopra V , Quinti L , Khanna P et al. LBH589, a hydroxamic acid-derived HDAC inhibitor, is neuroprotective in mouse models of Huntington’s disease. J. Huntingtons Dis. 5(4), 347–355 (2016).
   PubMedGoogle Scholar
• Siebzehnrubl FA , Raber KA , Urbach YK et al. Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proc. Natl Acad. Sci. USA 115(37), E8765–E8774 (2018).
   PubMed Web of Science ®Google Scholar
• Dompierre JP , Godin JD , Charrin BC et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington’s disease by increasing tubulin acetylation. J. Neurosci. 27(13), 3571–3583 (2007).
   PubMed Web of Science ®Google Scholar
• Hu Y , Chopra V , Chopra R et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc. Natl Acad. Sci. USA 108(41), 17141–17146 (2011).
   PubMed Web of Science ®Google Scholar
• Chopra V , Quinti L , Kim J et al. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s disease mouse models. Cell Rep. 2(6), 1492–1497 (2012).
   PubMed Web of Science ®Google Scholar
• Jia H , Wang Y , Morris CD et al. The effects of pharmacological inhibition of histone deacetylase 3 (HDAC3) in Huntington’s disease mice. PLOS ONE 11(3), e0152498 (2016).
   PubMed Web of Science ®Google Scholar
• Narayan P , Reid S , Scotter EL et al. Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains. Neurobiol. Dis. 146, 105092 (2020).
   PubMed Web of Science ®Google Scholar
• Beaver M , Bhatnagar A , Panikker P et al. Disruption of Tip60 HAT mediated neural histone acetylation homeostasis is an early common event in neurodegenerative diseases. Sci. Rep. 10(1), 18265 (2020).
   PubMed Web of Science ®Google Scholar
• Stott AJ , Maillard MC , Beaumont V et al. Evaluation of 5-(trifluoromethyl)-1,2,4-oxadiazole-based class IIa HDAC inhibitors for Huntington’s disease. ACS Med. Chem. Lett. 12(3), 380–388 (2021).
   PubMed Web of Science ®Google Scholar
• Farago A , Zsindely N , Farkas A et al. Acetylation state of lysine 14 of histone H3.3 affects mutant huntingtin induced pathogenesis. Int. J. Mol. Sci. 23(23), (2022).
   Web of Science ®Google Scholar
• Alcala-Vida R , Lotz C , Brule B et al. Altered activity-regulated H3K9 acetylation at TGF-beta signaling genes during egocentric memory in Huntington’s disease. Prog. Neurobiol. 219, 102363 (2022).
   PubMed Web of Science ®Google Scholar
• Arancibia-Opazo S , Contreras-Riquelme JS , Sanchez M et al. Transcriptional and histone acetylation changes associated with CRE elements expose key factors governing the regulatory circuit in the early stage of Huntington’s disease models. Int. J. Mol. Sci. 24(13), (2023).
   PubMed Web of Science ®Google Scholar
• Li E , Choi J , Sim HR et al. A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington’s disease. BMB Rep. 56(2), 178–183 (2023).
   PubMedGoogle Scholar
• Bobrowska A , Paganetti P , Matthias P , Bates GP . Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington’s disease. PLOS ONE 6(6), e20696 (2011).
   PubMed Web of Science ®Google Scholar
• Benn CL , Butler R , Mariner L et al. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington’s disease. PLOS ONE 4(6), e5747 (2009).
   PubMed Web of Science ®Google Scholar
• Ma C , D’Mello SR . Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. J. Biol. Chem. 286(6), 4819–4828 (2011).
   PubMed Web of Science ®Google Scholar
• Jeong H , Cohen DE , Cui L et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat. Med. 18(1), 159–165 (2011).
   PubMed Web of Science ®Google Scholar
• Duan W . Targeting sirtuin-1 in Huntington’s disease: rationale and current status. CNS Drugs 27(5), 345–352 (2013).
   PubMed Web of Science ®Google Scholar
• Tulino R , Benjamin AC , Jolinon N et al. Correction: SIRT1 activity is linked to its brain region-specific phosphorylation and is impaired in Huntington’s disease mice. PLOS ONE 11(2), e0150682 (2016).
   PubMed Web of Science ®Google Scholar
• Pallos J , Bodai L , Lukacsovich T et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease. Hum. Mol. Genet. 17(23), 3767–3775 (2008).
   PubMed Web of Science ®Google Scholar
• Sussmuth SD , Haider S , Landwehrmeyer GB et al. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington’s disease. Br. J. Clin. Pharmacol. 79(3), 465–476 (2015).
   PubMed Web of Science ®Google Scholar
• Wossner N , Alhalabi Z , Gonzalez J et al. Sirtuin 1 inhibiting thiocyanates (S1th)–a new class of isotype selective inhibitors of NAD(+) dependent lysine deacetylases. Front. Oncol. 10, 657 (2020).
   PubMed Web of Science ®Google Scholar